Business
Mustang Bio Announces Updated Interim Results from Follicular Lymphoma Cohort of Ongoing Phase 1/2 Clinical Trial of MB-106, CD20-Targeted CAR T Therapy
94% overall response rate and 78% complete response rate in patients with FL, including complete response in a patient previously treated with CD19-targeted
About this update from Mustang Bio, Inc.
[{"type":"text","content":"94% overall response rate and 78% complete response rate in patients with FL, including complete response in a patient previously treated with CD19-targeted CAR T therapy 100% overall response rate in other B-cell non-Hodgkin lymphomas including Waldenstrom macroglobulinemia and diffuse large B-cell lymphoma Multicenter Phase 1/2 clinical trial evaluating the safety and efficacy of MB-106 for relapsed or refractory B-NHL and CLL under Mustang’s IND open to enrollment WORCESTER, Mass., June 13, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that updated interim data from the ongoing Phase 1/2 clinical trial of MB-106, a CD20-targeted, autologous CAR T cell therapy, show a favorable safety profile, high overall response (“ORR”) and complete response (“CR”) rates, and CAR T persistence in patients with follicular lymphoma (“FL”). MB-106 is being developed in a collaboration between Mustang and Fred Hutchinson Cancer Center (“Fred Hutch”) to treat patients with relapsed or refractory B-cell non-Hodgkin lymphomas (“B-NHLs”) and chronic lymphocytic leukemia (“CLL”). The updated results presented during an on-site oral presentation at the European Hematology Association 2022 Hybrid Congress (“EHA2022”) by Mazyar Shadman, M.D., M.P.H., Associate Professor and physician at Fred Hutch and University of Washington, included interim safety and efficacy data from the cell manufacturing process that was modified to combine the culture of CD4+ and CD8+ cells. CAR-T cells were administered at one of 5 dose levels: 1x105, 3.3x105, 1x106, 3.3x106 and 1x107 CAR T cells/kg. Treatment for all patients was infused in the outpatient setting except for the first patient of each dose cohort, each of which was kept for overnight observation. In the 18 treated patients with FL, ORR and CR were 94% (17/18) and 78% (14/18), respectively. Additionally, 17% experienced a partial response (3/18) and 5% experienced disease progression (1/18). One patient experienced pseudo-progression followed by a spontaneous CR documented at 207 days and has remained in remission since. Additionally, one patient with prior CD19 CAR...